

April 9, 2020

Abbott Point of Care Inc. Susan Tibedo Director, Regulatory Affairs 400 College Road East Princeton, NJ 08540

Re: K200492

Trade/Device Name: i-STAT CG4+ Cartridge with the i-STAT 1 System Regulation Number: 21 CFR 862.1120 Regulation Name: Blood Gases (PCO2, PO2) and Blood pH Test System Regulatory Class: Class II Product Code: CHL, KHP Dated: February 27, 2020 Received: February 28, 2020

Dear Susan Tibedo:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <u>https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems</u>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<u>https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance</u>) and CDRH Learn (<u>https://www.fda.gov/training-and-continuing-education/cdrh-learn</u>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<u>https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice</u>) for more information or contact DICE by email (<u>DICE@fda.hhs.gov</u>) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Marianela Perez-Torres, Ph.D. Acting Deputy Director Division of Chemistry and Toxicology Devices OHT7: Office of In Vitro Diagnostics and Radiological Health Office of Product Evaluation and Quality Center for Devices and Radiological Health

Enclosure

Indications for Use

510(k) Number *(if known)* K200492

Device Name

i-STAT CG4+ cartridge with the i-STAT 1 System

Indications for Use (Describe)

The i-STAT CG4+ cartridge with the i-STAT 1 System is intended for use in the in vitro quantification of pH, PO2, PCO2, and lactate in arterial or venous whole blood in point of care or clinical laboratory settings.

pH, PO2, and PCO2 measurements are used in the diagnosis, monitoring, and treatment of respiratory disturbances and metabolic and respiratory-based acid-base disturbances.

Lactate measurements are used in (1) the diagnosis and treatment of lactic acidosis in conjunction with measurements of blood acid/base status, (2) monitoring tissue hypoxia and strenuous physical exertion, and (3) diagnosis of hyperlactatemia.

Type of Use	(Select one	or both.	as applicable)
1 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	1001001 0110	01 00011, 0	

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff *PRAStaff@fda.hhs.gov*

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

510(k) Summary

The information in this 510(k) summary is being submitted in accordance with the requirements of 21 CFR 807.92.

1.	Submitter Information	
	Owner	Abbott Point of Care Inc.
		400 College Road East Princeton, NJ 08540
		Fillectoli, NJ 08540
	Contact	Primary: Susan Tibedo
		Director Regulatory Affairs
		susan.tibedo@abbott.com
		Phone: 609-454-9360
		Secondary: Maria Figueroa
		Manager Regulatory Affairs
		maria.l.figueroa@abbott.com
		Phone: 609-454-9271
	Date Prepared	April 7, 2020

2. Device Information

Proprietary Name	i-STAT CG4+ cartridge with the i-STAT 1 System
Common Name	Blood gas test, analyzer, handheld
510(k) Number	K200492

Product code	Device Classification name	Regulation Number	Class	Panel	
CHL	Electrode, Ion Specific, pH	862.1120	П	Clinical Chemistry	
CHL	Electrode, Ion Specific, <i>p</i> CO ₂	862.1120	Ш	Clinical Chemistry	
CHL	Electrode, Ion Specific pO2	862.1120	П	Clinical Chemistry	
KHP	Electrode, Ion Specific, Lactate	862.1450	I	Clinical Chemistry	

3. Predicate Device

Proprietary Name epoc Lactate test, epoc Blood Analysis System

510(k) Number K093297

Product code	Device Classification name	Regulation Number	Class	Panel
KHP	Electrode, Ion Specific, Lactate	862.1450	Ι	Clinical Chemistry

Proprietary Name ABL800 FLEX blood gas, oximetry, electrolyte and metabolite analyzer

510(k) Number K041874

Product code	Device Classification name	Regulation Number	Class	Panel
CHL	Electrode, Ion Specific, pH	862.1120	Ш	Clinical Chemistry
CHL	Electrode, Ion Specific, <i>P</i> CO ₂	862.1120	II	Clinical Chemistry
CHL	Electrode, Ion Specific <i>P</i> O ₂	862.1120	II	Clinical Chemistry

4. Device Description

The i-STAT CG4+ test cartridge contains test reagents to analyze whole blood at the point of care or in the clinical laboratory for pH, *P*O₂ (partial pressure of oxygen), *P*CO₂ (partial pressure of carbon dioxide), and lactate. The test is contained in a single-use, disposable cartridge. Cartridges require two to three drops of whole blood which are typically applied to the cartridge using a transfer device.

The i-STAT 1 Analyzer is a handheld, *in vitro* diagnostic analytical device designed to run only i-STAT test cartridges. The instrument interacts with the cartridge to move fluid across the sensors and generate a quantitative result (within approximately 2 minutes).

The i-STAT 1 System is comprised of the i-STAT 1 analyzer, the i-STAT test cartridges and accessories (i-STAT 1 Downloader/Recharger, electronic simulator and portable printer). The system is designed for use by trained medical professionals at the patient point of care or in the clinical laboratory and is for prescription use only.

5. Intended Use Statement

The i-STAT CG4+ cartridge with the i-STAT 1 System is intended for use in the *in vitro* quantification of pH, PO₂, PCO₂, and lactate in arterial or venous whole blood in point of care or clinical laboratory settings.

pH, PO₂, and PCO₂ measurements are used in the diagnosis, monitoring, and treatment of respiratory disturbances and metabolic and respiratory-based acid-base disturbances.

Lactate measurements are used in (1) the diagnosis and treatment of lactic acidosis in conjunction with measurements of blood acid/base status, (2) monitoring tissue hypoxia and strenuous physical exertion, and (3) diagnosis of hyperlactatemia.

	ilarities and Differences: System (Test and	
Feature or	Predicate:	Candidate: pH test in the
Characteristic	ABL800 FLEX pH Test	i-STAT CG4+ cartridge with
	(K041874)	the i-STAT 1 System
Intended Use	The ABL800 FLEX is intended for <i>in vitro</i> testing of samples of whole blood for the parameters pH, pO ₂ , pCO ₂ , potassium, sodium, calcium, chloride, glucose, lactate, total bilirubin, and co-oximetry parameters (total hemoglobin, oxygen saturation, and the hemoglobin fractions FO ₂ Hb, FCOHb, FMetHb, FHHb, and FHbF). In addition the ABL800 FLEX is intended for <i>in vitro</i> testing of samples of expired air for the parameters pO ₂ and pCO ₂ . The ABL800 FLEX includes an AutoCheck Module to perform automated analysis of quality control fluids.	The i-STAT CG4+ cartridge with the i-STAT 1 System is intended for use in the <i>in vitro</i> quantification of pH in arterial or venous whole blood in point of care or clinical laboratory settings. pH measurements are used in the diagnosis, monitoring, and treatment of respiratory disturbances and metabolic and respiratory-based acid-base disturbances.
Demorrichia	of the pH/blood gas measurement. The normal function of many metabolic processes requires a pH to be within a relatively narrow range.	Dependeble Depender 7,000 - 7,700
Reportable Range	Test Range: ¹ 7.0 – 7.7 Measuring Range: ² 6.300 – 8.000	Reportable Range: 7.000 – 7.700
Sample Type	Arterial, venous or capillary whole blood	Arterial or venous whole blood
Sample Volume	At least 50 – 70 μL	95 µL

6. Summary Comparison of Technological Characteristics

¹ The **measuring range** for a parameter is the range within which the analyzer is physically capable of measuring. The measuring range corresponds to the "range of indication" as defined in the International vocabulary of basic and general terms in metrology" (VIM).

² The **test range** for a parameter is the range within which accuracy and precision of a measured parameter has been specified and intended to lie within specified limits. The test range corresponds to the "measuring range" as defined in the "International vocabulary of basic and general terms in metrology" (VIM).

Simi	larities and Differences: System (Test and	d Instrument) for pH
Feature or	Predicate:	Candidate: pH test in the
Characteristic	ABL800 FLEX pH Test	i-STAT CG4+ cartridge with
	(K041874)	the i-STAT 1 System
Sample	Ready to Use	Ready to Use
Preparation		
Traceability	BMS™ Mk2	NIST SRM 186-I, 186-II, 185, and 187
Calibration	1-point intervals 30 min, 1 hour, 2 hours	1-point on-board contained within the cartridge
Time to Test	Analyze heparinized samples within 30	Heparinized samples: within 10
(Sample	minutes after collection	minutes of collection
Stability)		
Principle of	Ion selective electrode	Ion selective electrode
Measurement		
Reagent Format	Reagent handling system, stored within analyzer	Cartridge
Analyzer Type	Floor Model	Handheld
		Hananola

Simila	rities and Differences: System (Test and	Instrument) for <i>P</i> O ₂
Feature or	Predicate:	Candidate: PO2 test in the
Characteristic	ABL800 FLEX pO ₂ Test	i-STAT CG4+ cartridge with
	(K041874)	the i-STAT 1 System
Intended Use	The ABL800 FLEX is intended for in vitro	The i-STAT CG4+ cartridge with
	testing of samples of whole blood for the	the i-STAT 1 System is intended
	parameters pH, pO ₂ , pCO ₂ , potassium,	for use in the <i>in vitro</i> quantification
	sodium, calcium, chloride, glucose, lactate,	of PO_2 in arterial or venous whole
	total bilirubin, and co-oximetry parameters	blood in point of care or clinical
	(total hemoglobin, oxygen saturation, and the	laboratory settings.
	hemoglobin fractions FO ₂ Hb, FCOHb,	laboratory settings.
	FMetHb, FHHb, and FHbF). In addition the	PO_2 measurements are used in the
	ABL800 FLEX is intended for in vitro testing	diagnosis, monitoring, and
	of samples of expired air for the parameters	treatment of respiratory
	pO_2 and pCO_2 . The ABL800 FLEX includes	disturbances and metabolic and
	an AutoCheck Module to perform automated	respiratory-based acid-base
	analysis of quality control fluids.	disturbances.
	analysis of quality control hulds.	distuibances.
	The arterial oxygen tension is an indicator of	
	the oxygen uptake in the lungs.	
Reportable	Test Range: ¹	Reportable Range:
Range	15 – 530 mmHg	15 - 530 mmHg
Ralige	15 – 550 mmg	2.00 – 70.49 kPa
	Measuring Range: ²	2.00 – 70.49 KFa
	0.0 - 800 mmHg	
	0.00 – 107 kPa	
Sample Type	Arterial, venous or capillary whole blood	Arterial or venous whole blood
Sample Volume	At least 50 – 70 μL	95 µL
Sample	Ready to Use	Ready to Use
Preparation		
Traceability	NIST certified Standard Reference Materials	NIST standard reference materials
		via commercially available certified
		specialty medical gas standards
Calibration	1-point intervals 30 min, 1 hour, 2 hours	1-point on-board contained within
	·	the cartridge
Time to Test	Analyze heparinized samples within 30	Heparinized samples: within 10
(Sample Stability)	minutes after collection	minutes of collection
(
Principle of	Amperometric measurement of oxygen	Amperometric measurement of
Measurement	reduction current	oxygen reduction current
Reagent Format	Reagent handling system, stored within	Cartridge
	analyzer	_
Analyzer Type	Floor Model	Handheld
		L

¹ The **measuring range** for a parameter is the range within which the analyzer is physically capable of measuring. The measuring range corresponds to the "range of indication" as defined in the International vocabulary of basic and general terms in metrology" (VIM).

² The **test range** for a parameter is the range within which accuracy and precision of a measured parameter has been specified and intended to lie within specified limits. The test range corresponds to the "measuring range" as defined in the "International vocabulary of basic and general terms in metrology" (VIM).

Similar	rities and Differences: System (Test and	Instrument) for <i>P</i> CO ₂
Feature or	Predicate:	Candidate: PCO ₂ test in the
Characteristic	ABL800 FLEX pCO ₂ Test	i-STAT CG4+ cartridge with
	(K041874)	the i-STAT 1 System
Intended Use	The ABL800 FLEX is intended for in vitro	The i-STAT CG4+ cartridge with
	testing of samples of whole blood for the	the i-STAT 1 System is intended
	parameters pH, pO ₂ , pCO ₂ , potassium,	for use in the <i>in vitro</i> quantification
	sodium, calcium, chloride, glucose, lactate,	of <i>P</i> CO ₂ in arterial or venous whole
	total bilirubin, and co-oximetry parameters	blood in point of care or clinical
	(total hemoglobin, oxygen saturation, and the hemoglobin fractions FO ₂ Hb, FCOHb,	laboratory settings.
	FMetHb, FHHb, and FHbF). In addition the	PCO₂ measurements are used in
	ABL800 FLEX is intended for in vitro testing	the diagnosis, monitoring, and
	of samples of expired air for the parameters	treatment of respiratory
	pO ₂ and pCO ₂ . The ABL800 FLEX includes	disturbances and metabolic and
	an AutoCheck Module to perform automated	respiratory-based acid-base
	analysis of quality control fluids.	disturbances.
	pCO ₂ is a direct reflection of the adequacy of	
	alveolar ventilation in relation to the metabolic rate.	
Reportable	Test Range: ¹	Reportable Range:
Range	15 – 150 mmHg	15.0 – 130.0 mmHg
		2.00 –17.29 kPa
	Measuring Range: ²	
	5.0 – 250 mmHg	
	0.67 – 33.3 kPa	
Sample Type	Arterial, venous or capillary whole blood	Arterial or venous whole blood
Sample Volume	At least 50 – 70 μL	95 µL
Sample	Ready to Use	Ready to Use
Preparation		
Traceability	NIST certified Standard Reference Materials	NIST standard reference materials
		via commercially available certified
Calibration	4 maint intervals 20 min. 4 hours 2 hours	specialty medical gas standards
Calibration	1-point intervals 30 min, 1 hour, 2 hours	1-point on-board contained within the cartridge
Time to Test	Analyze heparinized samples within 30	Heparinized samples: within 10
(Sample Stability)	minutes after collection	minutes of collection
Principle of	Ion selective electrode	Ion selective electrode
Measurement		
Reagent Format	Reagent handling system, stored within	Cartridge
	analyzer	
Analyzer Type	Floor Model	Handheld

¹ The **measuring range** for a parameter is the range within which the analyzer is physically capable of measuring. The measuring range corresponds to the "range of indication" as defined in the International vocabulary of basic and general terms in metrology" (VIM).

² The **test range** for a parameter is the range within which accuracy and precision of a measured parameter has been specified and intended to lie within specified limits. The test range corresponds to the "measuring range" as defined in the "International vocabulary of basic and general terms in metrology" (VIM).

Similari	Similarities and Differences: System (Test and Instrument) for Lactate							
Feature or	Predicate:	Candidate: Lactate test in the						
Characteristic	epoc Lactate Test with epoc Blood	i-STAT CG4+ cartridge with						
	Analysis System	the i-STAT 1 System						
	(K093297)							
Intended Use	The Lactate test, as part of the epoc Blood	The i-STAT CG4+ cartridge with						
	Analysis System, is intended for use by	the i-STAT 1 System is intended						
	trained medical professionals as an in vitro	for use in the <i>in vitro</i> quantification						
	diagnostic device for the quantitative testing of samples of heparinized or un-	of lactate in arterial or venous						
	anticoagulated arterial, venous or capillary	whole blood in point of care or clinical laboratory settings.						
	whole blood in the laboratory or at the point	clinical laboratory settings.						
	of care in hospitals, nursing homes or other	Lactate measurements are used in						
	clinical institutions.	(1) the diagnosis and treatment of						
		lactic acidosis in conjunction with						
	Lactate measurements from the epoc Blood	measurements of blood acid/base						
	Analysis System are used to evaluate the	status, (2) monitoring tissue						
	acid-base status and are used in the	hypoxia and strenuous physical						
	diagnosis and treatment of lactic acidosis	exertion, and (3) diagnosis of						
Deportable	(abnormally high acidity of the blood.)	hyperlactatemia.						
Reportable Range	Reportable Range: 0.30 – 20.00 mmol/L	Reportable Range: 0.30 – 20.00 mmol/L						
Range	2.7 – 180.2 mg/dL	2.7 – 180.2 mg/dL						
	0.03 – 1.80 g/L	2.1 100.2 mg/dE						
Sample Type	Arterial, venous or capillary whole blood	Arterial or venous whole blood						
Sample Volume	At least 92 µL	95 µL						
Sample	Ready to Use	Ready to Use						
Preparation								
Traceability	Certified standard reference material not	Certified standard reference						
	available at present	material not available at present						
Calibration	1-point on-board contained within the card	1-point on-board contained within						
		the cartridge						
Time to Test	Immediately after collection or in less than 5	Immediately after collection						
(Sample Stability)	minutes							
Principle of	Amperometric measurement of oxidized	Amperometric measurement of						
Measurement	hydrogen peroxide produced by lactate	oxidized hydrogen peroxide						
	oxidase activity	produced by lactate oxidase						
		activity						
Reagent Format	Test card	Cartridge						
Analyzer Type	Handheld	Handheld						

7. Performance Characteristics

Analytical Performance

a. Precision

Precision 20 days (Aqueous Materials)

Table 4, 00 Day Drasisian of CTAT all DO DOO

The precision of the i-STAT pH, PO₂, PCO₂, and Lactate tests in the i-STAT CG4+ blue cartridge with the i-STAT 1 System was evaluated using 5 levels of aqueous materials. This 20-day multi-day precision testing was based on CLSI document EP05-A3: *Evaluation of Precision of Quantitative Measurement Procedures; Approved Guideline-Third Edition.* The study was conducted using multiple instruments and one test cartridge lot over 20 days at one site. Total precision ('within-laboratory'), withinrun, between-run, and between-day were estimated for each level. The results of the 20day precision study are shown in **Table 1**.

..

Table 1: 20-Day Precision of i-STAT pH, PO ₂ , PCO ₂ , and Lactate tests on the i-STAT 1 Analyzer											
i-STAT	Fluid	N	Mean	Total		Within-run		Between-run		Between-day	
Test	Level	IN	Weall	SD	%CV	SD	%CV	SD	%CV	SD	%CV
	CV L1	80	6.5215	0.00435	0.07	0.00347	0.05	0.00228	0.03	0.00129	0.02
	CV L2	81	7.0199	0.00287	0.04	0.00252	0.04	0.00040	0.01	0.00132	0.02
pН	CV L3	80	7.4758	0.00279	0.04	0.00250	0.03	0.00098	0.01	0.00075	0.01
	CV L4	80	7.7551	0.00241	0.03	0.00209	0.03	0.00071	0.01	0.00097	0.01
	CV L5	80	7.9862	0.00369	0.05	0.00322	0.04	0.00118	0.01	0.00135	0.02
	CV L1	80	70.2	2.45	3.5	2.08	3.0	0.70	1.0	1.08	1.5
	CV L2	81	85.7	2.69	3.1	2.40	2.8	0.76	0.9	0.93	1.1
PO ₂ (mmHg)	CV L3	80	120.4	2.66	2.2	2.25	1.9	1.18	1.0	0.81	0.7
(3/	CV L4	80	152.9	3.02	2.0	1.88	1.2	1.78	1.2	1.55	1.0
	CV L5	80	363.4	6.98	1.9	4.15	1.1	5.07	1.4	2.40	0.7
	CV L1	80	87.08	1.349	1.5	0.916	1.1	0.872	1.0	0.470	0.5
PCO ₂	CV L2	81	59.48	0.921	1.5	0.872	1.5	0.228	0.4	0.190	0.3
(mmHg)	CV L3	80	29.24	0.675	2.3	0.617	2.1	0.227	0.8	0.151	0.5
	CV L4	80	21.14	0.552	2.6	0.521	2.5	0.141	0.7	0.118	0.6
	CV L5	80	15.05	0.506	3.4	0.473	3.1	0.138	0.9	0.114	0.8
	CV L1	80	18.448	0.1655	0.9	0.1505	0.8	0.0266	0.1	0.0634	0.3
1 + - +	CV L2	80	7.967	0.0495	0.6	0.0459	0.6	0.0132	0.2	0.0128	0.2
Lactate (mmol/L)	CV L3	79	2.251	0.0082	0.4	0.0073	0.3	0.0030	0.1	0.0021	0.1
	CV L4	80	0.924	0.0122	1.3	0.0108	1.2	0.0038	0.4	0.0041	0.4
	CV L5	80	0.497	0.0133	2.7	0.0123	2.5	0.0033	0.7	0.0037	0.7

Precision (Whole Blood)

Whole blood precision was evaluated using whole blood venous and arterial specimens collected with lithium heparin. The repeatability analysis was conducted using the data collected across multiple point of care sites. The mean values for each sample were divided into subintervals for each sample type. The results are provided in **Table 2** below:

Table 2: Precision for venous and arterial whole blood								
i-STAT Test	Units	Sample Type	Sample Range	N	Mean	SD	CV (%)	
	pH units	Venous Whole Blood	<7.30	20	7.202	0.0064	0.09	
			7.30 – 7.45	77	7.374	0.0060	0.08	
рН			>7.45	7	7.585	0.0030	0.04	
pri	priums	Arterial Whole Blood	<7.30	22	7.259	0.0059	0.08	
			7.30 – 7.45	119	7.389	0.0060	0.08	
			>7.45	36	7.494	0.0047	0.06	
		Venous Whole Blood	<50	59	28.8	0.9	3.0	
			50 - 100	27	58.2	2.0	3.4	
			100 - 250	4	188.6	1.4	0.7	
PO ₂	mmHg		>250	6	450.0	12.4	2.8	
PO2		Arterial Whole Blood	<50	2	40.3	0.5	1.2	
			50 - 100	65	77.5	3.4	4.4	
			100 - 250	78	156.6	3.7	2.4	
			>250	33	355.6	8.5	2.4	
	mmHg	Venous Whole Blood Arterial Whole Blood	<35	6	16.83	0.29	1.7	
			35 - 62.5	83	46.23	0.77	1.7	
PCO ₂			>62.5	26	91.61	0.73	0.8	
F 002			<35	33	31.23	0.51	1.6	
			35 - 62.5	140	42.65	0.90	2.1	
			>62.5	4	74.36	0.37	0.5	
	mmol/L	Venous Whole Blood	<1.0	50	0.70	0.016	2.26	
Lactate			1.0 – 5.0	62	1.83	0.021	1.14	
			>5.0	11	12.88	0.200	1.55	
Laciale		Arterial Whole Blood	<1.0	57	0.72	0.018	2.49	
			1.0 – 5.0	42	1.87	0.020	1.08	
			>5.0	8	8.55	0.036	0.42	

b. Linearity

The study was designed based on CLSI EP06-A: *Evaluation of the Linearity of Quantitative Measurement Procedures*.

The linearity of the i-STAT pH, *PO*₂, *PCO*₂, and Lactate tests in the i-STAT CG4+ blue cartridge with the i-STAT 1 System was evaluated by preparing whole blood samples of varying analyte levels for each i-STAT test. The i-STAT pH, *PO*₂, *PCO*₂, and Lactate tests demonstrated linearity over the reportable range for each i-STAT test. Regression summary of the response for each i-STAT test versus the concentration of the whole blood samples of varying analyte levels is provided in **Table 3**.

i-STAT 1 Analyzer								
i-STAT Test	i-STAT Units Reportable Range Tested Slope Intercent r ²							
pН	pH units	7.0 – 7.7	6.889 – 7.979	0.966	0.246	0.9983		
PO ₂	mmHg	15 – 530	10.69 - 608.49	1.005	-0.196	0.9988		
PCO ₂	mmHg	15 – 130	10.75 – 151.02	1.027	-1.084	0.9978		
Lactate	mmol/L	0.30 - 20.00	0.222 – 21.742	1.128	0.104	0.9966		

Table 0. Downson's contraction for the COTAT DO DOO will so the state to state

c. Limit of Quantitation (LoQ)

The study was based on the CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline–Second Edition.

The LoQ of the i-STAT pH, PO₂, PCO₂, and Lactate tests in the i-STAT CG4+ blue cartridge were evaluated on the i-STAT 1 analyzer using whole blood that was altered to low pH (< 7 pH units), PO₂ (< 15 mmHg), PCO₂ (< 15 mmHg), and lactate (0.22 – 0.29 mmol/L) concentrations and two cartridge lots for each test. The LoQ for each of the i-STAT pH, PO₂, PCO₂, and Lactate tests was determined to be below the lower limit of the reportable range for each of the i-STAT tests as shown in Table 4.

Table 4: LoQ Results for the i-STAT <i>P</i> O ₂ , <i>P</i> CO ₂ , pH and Lactate tests on the i-STAT 1 Analyzer							
i-STAT Test Lower limit of the range Determined LoQ							
pH (pH units)	≤ 7.000 pH units	6.716					
PO ₂ (mmHg)	≤ 15 mmHg	10					
PCO ₂ (mmHg)	≤ 15.0 mmHg	9.7					
Lactate (mmol/L)	≤ 0.30 mmol/L	0.27					

d. Limit of Blank and Detection (LoB/LoD)

The study was based on CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline–Second Edition.

The LoB and LoD of the i-STAT Lactate test in the i-STAT CG4+ blue cartridge were evaluated on the i-STAT 1 analyzer using whole blood that was altered to a "blank" lactate concentration for LoB testing and two "low" lactate concentrations for LoD testing. The LoB and LoD were determined based on the maximal LoB or LoD value obtained for each lot tested. The determined LoB and LoD for the i-STAT Lactate test on the i-STAT 1 Analyzer are shown in the Table 5 below.

Table 5: Summary of LoB and LoD Results for the i-STATLactate test on the i-STAT 1 Analyzer						
i-STAT Test LoB LoD						
Lactate 0.15 mmol/L 0.19 mmol/L						

e. Oxygen Sensitivity for the Lactate Test

The effect on oxygen on the i-STAT Lactate test in the i-STAT CG4+ blue cartridge was evaluated with high and low ranges of oxygen. The equivalency between the high and low conditions was determined by a two-sample equivalence test using the analyte allowable error (Ea) relative to the analyte control mean/median results.

The study demonstrated that the i-STAT Lactate test in the i-STAT CG4+ blue cartridge is insensitive to oxygen changes between 20 to >500 mmHg.

f. Interference

The interference performance of the i-STAT pH, PO₂, PCO₂, and Lactate tests in the i-STAT CG4+ blue cartridge on the i-STAT 1 analyzer was evaluated using whole blood samples based on CLSI EP07 ED3: *Interference Testing in Clinical Chemistry, Third Edition*. The effect of each substance was evaluated by comparing the performance of a control sample, spiked with blank solvent solution, with the test results from a sample spiked with the potentially interfering substance at the toxic/pathological concentration based on CLSI EP37 ED1: *Supplemental Tables for Interference Testing in Clinical Chemistry, First Edition*, as applicable. A substance was identified as an interferent if the difference between the control and test samples was outside of the allowed error (Ea) for the i-STAT test.

Table 6 and **Table 7** contain the lists of potentially interfering substances tested for the i-STAT pH, *PO*₂, *PCO*₂, and Lactate tests and the interference results.

Table 6: PCO ₂	Table 6: Potentially Interfering Substances and Test Concentration for pH, PO ₂ , and PCO ₂						
i-STAT	Substance	Test Conce	Test Concentration		Interference		
Test	Substance	mmol/L	mg/dL	(Yes/No)	Results		
	Acetaminophen	1.03	15.6	No			
	Atracurium ¹	0.0287	3.57	No			
	Calcium	5.0	20	No			
	Ethanol	130	600	No			
	Ibuprofen	1.06	21.9	No			
PO ₂	Morphine	0.0273	0.78	No			
PCO ₂	Potassium	8	59.6	No			
pН	Sodium	170	993.48	No			
	Bilirubin	0.684	40	No			
	Hemoglobin	10 g/L	1000	No			
	Triglyceride	16.94	1500	No			
	Intralipid	N/A	2493	No			
	Thiopental	1660	40.2	No			

¹ The test concentration for this substance is not included in CLSI guideline EP37 1st edition.

Table 7:	Table 7: Potentially Interfering Substances and Test Concentration for Lactate						
i-STAT	Substance	Test Concentration		Interference	Interference		
Test	Substance	mmol/L	mg/dL	(Yes/No)	Results		
	Acetaldehyde ¹	45 µmol/L	0.20	No			
	Acetaminophen	1.03	15.6	No			
	N-Acetyl-Cysteine	0.92	15.0	No			
	Ascorbic Acid	0.298	5.25	No			
	β-Hydroxybutyric Acid ¹	6	62	No			
	Bilirubin	0.684	40	No			
	Bromide ¹	40.7	325.7	Yes	Decreased results ≥ 40.7 mmol/L		
	Dopamine	4.06 µmol/L	0.0621	No			
Lactate	Formaldehyde ¹	0.133	0.399	No			
	Glycolic Acid ¹	10.0	76.1	Yes	Increased results ≥ 1.18 mmol/L		
	Hemoglobin	10 g/L	1000	No			
	Hydroxyurea	0.405	3.08	No			
	Pyruvate	0.570	5	No			
	Salicylate	0.207	2.86	No			
	Thiocyanate	0.898	5.22	No			
	Triglyceride	16.94	1500	No			
	Intralipid	N/A	3423	No			
	Uric Acid	1.4	23.5	No			

Comparison Study

g. Method Comparison with Predicate Device

Method comparison data was demonstrated in a study based on CLSI guideline EP09c-ED3. Lithium heparin venous and arterial blood specimens were evaluated and analyzed on the i-STAT 1 analyzer against whole blood specimens tested on the comparative method. For pH, PO₂, and PCO₂, a Passing Bablok linear regression analysis was performed using the first replicate result from the i-STAT CG4+ cartridge with the i-STAT 1 System versus the singlicate result of Radiometer ABL800 FLEX. For lactate, the first replicate result from the i-STAT CG4+ cartridge with the i-STAT 1 System was compared to the mean result of epoc® Blood Analysis System.

The results of the method comparison of venous whole blood and arterial whole blood samples is presented in **Table 8**.

Table 8: Method Comparison Results for venous and arterial whole blood						
i-STAT Test	Ν	Slope	Intercept	r		
pН	316	1.05	-0.34	0.97		
P O ₂	308	1.03	-3.96	0.99		
P CO ₂	327	1.01	-1.29	0.99		
Lactate	246	0.96	0.08	1.00		

8. Conclusion

The results of these studies demonstrate that performance of the i-STAT pH, *P*O₂, *P*CO₂, and Lactate tests in the i-STAT CG4+ blue cartridge with the i-STAT 1 System are substantially equivalent to the comparative method.